Palliative radiation therapy for metastatic Ewing sarcoma
Open Access
Abstract
BACKGROUND: Although radiotherapy is an accepted component of curative treatment for Ewing sarcoma (EWS), to the authors' knowledge, there are scant data evaluating its use for palliation. The authors reviewed the Duke University Medical Center experience to evaluate treatment response and response durability.METHODS: Between 1980 and 2002, 21 patients with metastatic EWS received palliative radiotherapy. Pain was the primary indication for treatment. The majority of patients were male (n = 16 patients), and the median age at diagnosis was 11.6 years (range, 2.7‐28.8 yrs). Fifty‐two percent of patients had metastases at initial diagnosis. For the others, the median interval from initial diagnosis to metastases was 1.7 years.RESULTS: Sixty‐three metastatic sites were irradiated (median dose, 30 gray [Gy]; range, 4.5‐68.5 Gy), and a median of 3 sites were treated per patient (range, 1‐16 sites per patient). At the time of last follow‐up, 1 patient with a solitary brain metastasis has been disease free for 3.4 years after resection and cranial radiotherapy; all other patients died of their disease. Censoring this survivor, patients lived for a median of 1.0 year after metastatic diagnosis (range, from 17 days to 6.8 years), 41 days of which were spent in treatment (range, 1‐93 days). Of all sites, 55% had a complete clinical response of symptoms, and 29% had a partial response. The median response duration was 4.0 months (range, 10 days to 4.8 years). Only the survivor was noted to have a treatment complication (growth hormone insufficiency).CONCLUSIONS: It was possible to treat metastatic EWS effectively with palliative radiotherapy. Because these patients live a median of 1 year after diagnosis of metastases, providing symptom relief without a protracted treatment course is valuable and appropriate therapy. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 14 references indexed in Scilit:
- Treatment of Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone: Evaluation of Combination Ifosfamide and Etoposide—A Children's Cancer Group and Pediatric Oncology Group StudyJournal of Clinical Oncology, 2004
- Ewing sarcoma: Radiation dose and target volumePediatric Blood & Cancer, 2004
- Metastatic Ewing sarcoma/PNET of bone at diagnosis: Prognostic factors—a report from Saudi ArabiaMedical and Pediatric Oncology, 2001
- Treatment strategies for metastatic Ewing's sarcomaEuropean Journal of Cancer, 2001
- Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients.Journal of Clinical Oncology, 1998
- A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studiesAnnals of Oncology, 1998
- Long-Term Follow-Up and Prognostic Factors in Ewing’s SarcomaOncology, 1997
- Ewing's sarcoma metastatic at diagnosis results and comparisons of two intergroup Ewing's sarcoma studiesCancer, 1990
- Metastatic Ewing's sarcoma: remission induction and survival.Journal of Clinical Oncology, 1987